40 /100
MEDIUM RISK
Score updated Jul 13, 2026

MRKR — Marker Therapeutics, Inc. Dilution Risk Tracker

Track MRKR dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track MRKR — Get alerts when the score changes →

As of July 13, 2026, Marker Therapeutics, Inc. (MRKR) has a DilutionWatch DilutionScore of 40/100, rated MEDIUM dilution risk. Marker Therapeutics, Inc. has a market capitalization of $26.18M, 16.67M shares outstanding, 36 institutional holders tracked. Key dilution vectors include 716.8K outstanding warrants, approximately 11 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
65
📊 Float Risk
12
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
27%
🔄 Reverse Split 40%
• 50-day avg $1.46 approaching $1 threshold
• 11 months cash with weak price
💰 Capital Raise 15%
• Under 12 months cash (11mo)
🔁 Convertible Conversion 15%
• Convertible debt present: 14.8% potential dilution
🔔 Track MRKR — Get forecast alerts →

💹 Market Data

Market Cap$26.18M
Shares Outstanding16.67M
Float13.81M
Cash$14.92M
Debt$77.4K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↓ 7.2% shares (2026Q1 vs prior)
36 institutional holders · 4.29M shares
#1 NEA Management Company, LLC 1.63M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 778.6K shares
#3 Blue Owl Capital Holdings LP 554.2K shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest116.7K
Days to Cover2.2
% of Float0.8%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Jul 07, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2016
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for MRKR Shareholders

Marker Therapeutics, Inc. (MRKR) has a DilutionScore of 40/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch tracks 716,819 outstanding warrants for MRKR. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: MRKR has approximately 11 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for MRKR in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for MRKR alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Warrants Explained →
Track MRKR Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking MRKR — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for MRKR
📊 MRKR FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 MRKR Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.